参考文献/References:
[1] Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization [J]. EuroIntervention,2019,14(14):1435-1534.
[2] 中华医学会心血管病学分会动脉粥样硬化与冠心病学组,中华医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,等. 冠心病双联抗血小板治疗中国专家共识[J].中华心血管病杂志,2021,49(5):432-454.
[3] Cao D,Chandiramani R,Chiarito M,et al. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention:a 40-year journey[J]. Eur Heart J,2021,42(4):339-351.
[4] Brinza C,Burlacu A,Tinica G,et al. A systematic review on bleeding risk scores’ accuracy after percutaneous coronary interventions in acute and elective settings[J]. Healthcare (Basel),2021,9(2):148.
[5] Subherwal S,Bach RG,Chen AY,et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction:the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score[J]. Circulation,2009,119(14):1873-1882.
[6] Ariza-Solé A,Sánchez-Elvira G,Sánchez-Salado JC,et al. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Thromb Res,2013,132(6):652-658.
[7] Zhao XY,Li JX,Tang XF,et al. Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions[J]. Chin Med J (Engl),2018,131(3):262-267.
[8] Liu R,Zheng W,Zhao G,et al. Predictive validity of CRUSADE,ACTION and ACUITY-HORIZONS bleeding risk scores in Chinese patients with ST-segment elevation myocardial infarction[J]. Circ J,2018,82(3):791-797.
[9] Tscherny K,Kienbacher C,Fuhrmann V,et al. Risk stratification in acute coronary syndrome:Evaluation of the GRACE and CRUSADE scores in the setting of a tertiary care centre[J]. Int J Clin Pract,2020,74(2):e13444.
[10] Castini D,Centola M,Ferrante G,et al. Comparison of CRUSADE and ACUITY-HORIZONS bleeding risk scores in patients with acute coronary syndromes[J]. Heart Lung Circ,2019,28(4):567-574.
[11] Yildirim E,Uku O,Bilen MN,et al. Performance of HAS-BLED and CRUSADE risk scores for the prediction of haemorrhagic events in patients with stable coronary artery disease[J]. Cardiovasc J Afr,2019,30(4):198-202.
[12] Hamm CW,Bassand JP,Agewall S,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2011,32(23):2999-3054.
[13] Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J ,2021,42(14):1289-1367.
[14] Mehran R,Pocock SJ,Stone GW,et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes:a risk model from the ACUITY trial[J]. Eur Heart J,2009,30(12):1457-1466.
[15] Roongsangmanoon W,Chichareon P,Angkananard T,et al. External validation of ACUITY/HORIZON bleeding risk score among acute coronary syndrome patients in Thai PCI Registry [J]. Thromb Haemost,2023,123(2):255-266.
[16] Chen TY,Chung WJ,Lee CH,et al. Evaluation of bleeding risk in patients with acute myocardial infarction undergoing transradial percutaneous coronary intervention[J]. Int Heart J ,2019,60(3):577-585.
[17] Baber U,Mehran R,Giustino G,et al. Corona ry thrombosis and major bleeding after PCI with drug-eluting stents:risk scores from PARIS[J]. J Am Coll Cardiol,2016,67(19):2224-2234.
[18] 赵雪燕,杨进刚,范肖雪,等. PARIS出血评分对急性心肌梗死药物支架术后患者院内出血的预测价值——中国急性心肌梗死注册研究[J]. 中国循环杂志,2018,33(2):110-116.
[19] Chandrasekhar J,Baber U,Sartori S,et al. 1-Year COMBO stent outcomes stratified by the PARIS bleeding prediction score:From the MASCOT registry[J]. Int J Cardiol Heart Vasc,2020,31:100605.
[20] Yoshida R,Ishii H,Morishima I,et al. Performance of HAS-BLED,ORBIT,PRECISE-DAPT,and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention[J]. J Cardiol,2019,73(6):479-487.
[21] Costa F,van Klaveren D,James S,et al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score :a pooled analysis of individual-patient datasets from clinical trials[J]. Lancet,2017,389(10073):1025-1034.
[22] Choi KH,Song YB,Lee JM,et al. Clinical usefulness of PRECISE-DAPT score for predicting bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention :an analysis from the SMART-DATE randomized trial[J]. Circ Cardiovasc Interv,2020 May,13(5):e008530.
[23] Asif A,Sezer A,Thoma F,et al.Relationship between predicting bleeding complication in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score and mortality among patients with atrial fibrillation undergoing percutaneous coronary intervention[J]. Catheter Cardiovasc Interv,2021,98(5):838-845.
[24] Pamukcu HE,Tan?k VO,?im?ek B,et al. The association between the PRECISE-DAPT score and new-onset atrial fibrillation in patients with ST-elevation myocardial infarction[J]. J Tehran Heart Cent,2021,16(1):20-25.
[25] Sel?uk M,??nar T,?ayl?k F,et al. The association of a PRECISE-DAPT score with no-reflow in patients with ST-segment elevation myocardial infarction[J]. Angiology,2022,73(1):68-72.
[26] Natsuaki M,Morimoto T,Yamaji K,et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention:CREDO-Kyoto thrombotic and bleeding risk scores[J]. J Am Heart Assoc,2018,7(11):e008708.
[27] Yamashita D,Saito Y,Sato T,et al. Impact of PARIS and CREDO-Kyoto thrombotic and bleeding risk scores on clinical outcomes in patients with acute myocardial infarction[J]. Circ J,2022,86(4):622-629.
[28] Rozemeijer R,van Bezouwen WP,van Hemert ND,et al. Direct comparison of predictive performance of PRECISE-DAPT versus PARIS versus CREDO-Kyoto:a?subanalysis of the ReCre8 trial[J]. Neth Heart J,2021,29(4):201-214.
[29] Urban P,Mehran R,Colleran R,et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention:a consensus document from the Academic Research Consortium for High Bleeding Risk[J]. Eur Heart J,2019,40(31):2632-2653.
[30] Fujii T,Ikari Y. Predictive ability of academic research consortium for high bleeding risk criteria in ST-elevation myocardial infarction patients undergoing primary coronary intervention[J]. Circ J,2021,85(2):159-165.
[31] Gragnano F,Spirito A,Corpataux N,et al. Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition[J]. EuroIntervention,2021,17(11):e898-e909.
[32] Tsukizawa T,Fujihara M. Relationship between in-hospital event rates and high bleeding risk score in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction[J]. Cardiovasc Interv Ther,2022,37(3):490-496.
[33] Garot P,Neylon A ,Morice MC,et al. Bleeding risk differences after TAVR according to the ARC-HBR criteria:insights from SCOPE 2[J]. EuroIntervention,2022,18(6):503-513.
[34] Montalto C,Munafò AR,Arzuffi L,et al. Validation of the ARC-HBR criteria in 68,874 patients undergoing PCI:A systematic review and meta-analysis[J]. Hellenic J Cardiol,2022,66:59-66.
[35] Tan JWC,Chew DP,Brieger D,et al. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on antithrombotic management for high-risk chronic coronary syndrome[J]. Eur Cardiol,2021,16:e26.
[36] Dong L,Lu C,Wensen C,et al. Performance of PRECISE-DAPT and age-bleeding-organ dysfunction score for predicting bleeding complication during dual antiplatelet therapy in Chinese elderly patients[J]. Front Cardiovasc Med,2022,9:910805.
相似文献/References:
[1]周召锋,吴春阳.急性冠状动脉综合征的抗血小板治疗进展[J].心血管病学进展,2015,(5):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
ZHOU Zhaofeng,WU Chunyang.Development of Antiplatelet Therapy for Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2015,(4):646.[doi:10.3969/j.issn.1004-3934.2015.05.032]
[2]徐俊波 黄刚 蔡琳 刘汉雄 张廷杰.老老年患者抗血小板治疗的循证临床实践[J].心血管病学进展,2019,(8):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
XU Junbo,HUANG Gang,CAI Lin,et al.Evidence-based Antiplatelet Treatment in Very Elderly Patients in Clinical Practice[J].Advances in Cardiovascular Diseases,2019,(4):1123.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.013]
[3]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(4):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
[4]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(4):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
[5]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(4):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]徐蓉玮 王亚玲.冠状动脉非阻塞性心肌梗死抗血小板治疗作用[J].心血管病学进展,2022,(10):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
XU RongweiWANG Yaling.Role of Antiplatelet Therapy in Myocardial Infarction with Non-obstructive Coronary Arteries[J].Advances in Cardiovascular Diseases,2022,(4):888.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.006]
[7]吕易非 李紫凡 邵褀睿 韩江莉.急性冠脉综合征合并高出血风险患者双联抗血小板治疗研究进展[J].心血管病学进展,2023,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
LV Yifei,LI Zifan,SHAO Qirui,et al.Dual Antiplatelet Therapy for Patients with Acute Coronary Syndrome and High Bleeding Risk[J].Advances in Cardiovascular Diseases,2023,(4):577.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.001]
[8]努尔古丽·玉苏普 古力尼尕尔·麦麦提吐尔孙 陈清杰 艾尔肯·阿吉.急性冠脉综合征合并糖尿病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2023,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
Nurgul·Yusup,Gulinigar·Mamattursun,CHEN Qingjie,et al.P2Y12 Receptor Antagonist Therapy in A cute Coronary Syndrome with Diabetes[J].Advances in Cardiovascular Diseases,2023,(4):593.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.005]
[9]崔鸿杰 吴英锋.CYP2C19基因多态性指导抗血小板治疗的研究现状[J].心血管病学进展,2023,(11):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]
Cui Hongjie,Wu Yingfeng.CYP2C19 gene polymorphism for antiplatelet therapy[J].Advances in Cardiovascular Diseases,2023,(4):1019.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.014]